Small - but positive - increase in costs for hospital medicine in Denmark

27 August 2024

Spending on hospital medicine in Denmark increased by just under 6% in the first half of 2024, compared to the first six months of the year in 2023.

The growth is spread over quarters by 11.5% in the first three months, while in the second quarter it increased by 1.6%, noted the Danish pharma trade group Lif in a website posting.

These are mainly in the field of innovative drugs for cancer and rheumatic diseases, which are increasing expenses. Also, in the field of sclerosis, where a new drug recommendation for multiple sclerosis came into force on January 1, 2024, more drugs are being used.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK